Immuneering Corp Ordinary Shares Class A IMRX 深 沪
已收盘 09-19 16:00:00 美东时间
2.42
+0.140
+6.14%
华盛通- 最 高2.64
- 今 开2.43
- 成交量 411.03万股
- 最 低 2.275
- 昨 收 2.28
- 总市值 7086.56万
- 52周最高 9.00
- 市盈率 静 --
- 换手率 14.04%
- 52周最低 1.00
- 委 比 -95.49%
- 总股本 2928.33万
- 历史最高 33.99
- 量 比 0.08
- 振 幅 16.01%
- 历史最低 1.00
- 每 手 1
- 风险率 2.61%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Wall Street Analysts Are Bullish on Top Healthcare Picks
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts jus...
09-18 20:40
Can Immuneering (NASDAQ:IMRX) Afford To Invest In Growth?
Just because a business does not make any money, does not mean that the stock w...
09-17 20:43
美股盘前丨暴涨1850%！TNON完成定增募资；Adobe绩后暴跌8.7%
小盘医药股TNON暴涨1850%！公司完成定增募资；甲骨文涨超6%，提高下财年营收指引；Adobe重挫8.7%，下财季指引欠佳>>
09-13 16:22
受胰腺治疗试验积极成果提振 药物开发商Immuneering(IMRX.US)盘后飙升58%
周四，药物开发商Immuneering公司(IMRX.US)对其候选药物在2a期试验中报告了积极数据成果，股价大涨45%
09-13 10:55
Positive Phase 2a Trial Data Reinforces Buy Rating for Immuneering’s Stock
In a report released today, Ami Fadia from Needham maintained a Buy rating on I...
09-13 06:55
Immuneering stock rockets 45% on pancreatic therapy data
Immuneering (NASDAQ:IMRX) stock rocketed 45% post-market Thursday after the company reported positive Phase 2a data for its drug candidate IMM-1-104 in combination with modified gemcitabine/nab-paclit...
09-13 05:58
5Needham Reiterates Buy on Immuneering, Maintains $15 Price Target
Needham analyst Ami Fadia reiterates Immuneering (NASDAQ:IMRX) with a Buy and maintains $15 price target.
08-07 19:46
Nasdaq Surges 1%; Meta Posts Upbeat Earnings
U.S. stocks traded mostly higher this morning, with the Nasdaq Composite gainin...
08-01 22:15
Market-Moving News for August 1st
META: 8% | Meta shares are trading higher after the company reported better-than-expected Q2 financial results and issued Q3 guidance above estimates. IMRX: 60% | Immuneering shares are trading higher
08-01 20:21
Immuneering reports Q1 results
Immuneering press release (NASDAQ:IMRX): Q1 GAAP EPS of -$0.49 misses by $0.02. Cash, cash equivalents and marketable securities as of March 31 were $71.3M, compared with $85.7M as of December 31, 202...
05-08 22:50
